



Company Announcement no. 8/2014

To: NASDAQ OMX Copenhagen A/S

Hørsholm, Denmark, 20 marts 2014

**Warrant Programme - Registration of capital increase and new Articles of Association following warrant exercise**

With reference to Company Announcement no. 7/2014 of 20 March 2014, Veloxis Pharmaceuticals A/S announces that as a consequence of warrant exercise a capital increase of nominal 195,485.70 new shares with a nominal value of DKK 0.10 each has been registered with the Danish Business Authority today.

Following registration of the new shares, the share capital of Veloxis Pharmaceuticals A/S is nominal DKK 166,252,738.30 divided into shares of DKK 0.10 each.

Each share of nominal DKK 0.10 carries one vote at general meetings in Veloxis Pharmaceuticals A/S.

The new shares are expected to be admitted to trading and official listing on NASDAQ OMX Copenhagen on 24 March 2014 under the same identification code as the company's existing shares (ISIN: DK0060048148).

The amendment of the Articles of Association entailed by the capital increase has today also been registered with the Danish Business Authority. The new Articles of Association for Veloxis Pharmaceuticals A/S are attached to this announcement and are also available on the company's website: [www.veloxis.com](http://www.veloxis.com).

**For more information, please contact:**

Veloxis Pharmaceuticals A/S

Bill Polvino  
President & CEO  
Mobile: +1 917 647 9107  
Email: [wjp@veloxis.com](mailto:wjp@veloxis.com)

Johnny Stilou  
EVP, Chief Financial Officer  
Mobile: +45 21 227 227  
Email: [jst@veloxis.com](mailto:jst@veloxis.com)

**About Veloxis Pharmaceuticals**

Based in Horsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. The company's lead product candidate is Envarsus® for immunosuppression, specifically organ transplantation. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability at low scale up costs. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market that is commercialized through partner Santarus, Inc. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.

For further information, please visit [www.veloxis.com](http://www.veloxis.com).